PTC Therapeutics' CEO Stuart W. Peltz, Ph.D. Finalist For The 2015 NJBiz Innovation Hero Award
Please replace the press release from June 23rd, 10:30 am ET with the following corrected version. The corrected version reads:
PTC Therapeutics' CEO Stuart W. Peltz, Ph.D. Finalist For The 2015 NJBiz Innovation Hero Award
SOUTH PLAINFIELD, N.J., June 23, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its co-founder and Chief Executive Officer, Stuart W. Peltz, Ph.D., is a finalist for the Innovation Hero Award, a category in the 2015 NJBiz Healthcare Heroes awards program. The awards program honors individuals and organizations that significantly impact the quality of healthcare in New Jersey. The Innovation Hero Award recognizes an individual primarily responsible for the development of a new treatment that can save lives or improve the quality of life for a large number of people. The award ceremony took place today at the Palace at Somerset Park in Somerset, New Jersey.
"I appreciate this recognition honoring PTC's efforts to develop treatments for rare and devastating diseases," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics, Inc. "Last year, Translarna received marketing authorization in the European Union, making it the first-ever approved treatment for Duchenne muscular dystrophy. This marks an important milestone for patients suffering from this severe, debilitating muscle disorder. Our mission since starting the company over 17 years ago has been to make a significant difference in the lives of our patients and their families. We are excited about continuing this mission through our efforts to make Translarna globally available to all boys who may benefit from this treatment."
Through his pioneering research in RNA biology while at the Department of Molecular Genetics and Microbiology at the Robert Wood Johnson Medical School, Dr. Peltz recognized the potential of targeting RNA processes with small molecules to advance medical science and help patients in need. His work was instrumental in identifying and characterizing components of multiple mRNA decay and translation pathways. These findings have translated into several novel drug discovery platforms that enable PTC to develop potential new drugs across multiple therapeutic areas including genetic disorders, oncology, and infectious diseases. PTC's lead program from the nonsense suppression platform is Translarna, a protein restoration therapy for Duchenne muscular dystrophy.
ABOUT PTC THERAPEUTICS, INC.:
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.
FOR MORE INFORMATION:
Investors:
Emily Hill
+1(908) 912-9327
[email protected]
Media:
Jane Baj
+1 (908) 912-9167
[email protected]
FORWARD LOOKING STATEMENTS:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release, including statements regarding the future expectations, plans and prospects for PTC; PTC's ability to maintain the marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area, which is conditioned upon completion of PTC's Phase 3 confirmatory trial of Translarna in nmDMD, among other things, and subject to annual review and renewal by the EMA following its reassessment of the risk benefit balance of the authorization; the rate and degree of market acceptance and clinical utility of Translarna; the timing and scope of PTC's commercial and reimbursed early access program launches for Translarna in the European Economic Area and other territories; PTC's estimates regarding the potential market opportunity for Translarna, including the size of eligible patient populations and PTC's ability to identify such patients; the timing and conduct of PTC's clinical trials of Translarna for the treatment of DMD and CF as well as the timing and conduct of its earlier stage studies and programs; PTC's current and planned regulatory filings, including with the FDA and in the European Union; PTC's strategy and the objectives of management, are forward-looking statements. Other forward-looking statements may be identified by the words "plan," "guidance," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to its ability to commercialize Translarna in general and specifically as a treatment for nonsense mutation DMD, including its ability to successfully negotiate favorable pricing and reimbursement processes on a timely basis in the countries in which it may obtain regulatory approval, including the countries in the European Economic Area; the initiation, conduct and availability of data from clinical trials and studies; expectations for regulatory approvals; PTC's scientific approach and general development progress; the eligible patient base and commercial potential of Translarna and PTC's other product candidates and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.
SOURCE PTC Therapeutics, Inc.
Share this article